New advances in management and treatment of cardiac implantable electronic devices infections

Infection. 2024 Apr;52(2):323-336. doi: 10.1007/s15010-023-02130-8. Epub 2023 Nov 24.

Abstract

Cardiac implantable electronic devices (CIED) are increasingly used worldwide, and infection of these devices remains one of the most feared complications.CIED infections (CDIs) represent a challenge for physicians and the healthcare system in general as they require prolonged hospitalization and antibiotic treatment and are burdened by high mortality and high costs, so management of CDIs must be multidisciplinary.The exact incidence of CDIs is difficult to define, considering that it is influenced by various factors mainly represented by the implanted device and the type of procedure. Risk factors for CDIs could be divided into three categories: device related, patient related, and procedural related and the etiology is mainly sustained by Gram-positive bacteria; however, other etiologies cannot be underestimated. As a matter of fact, the two cornerstones in the treatment of these infections are device removal and antimicrobial treatment. Finally, therapeutic drug monitoring and PK/PD correlations should be encouraged in all patients with CDIs receiving antibiotic therapy and may result in a better clinical outcome and a reduction in antibiotic resistance and economic costs.In this narrative review, we look at what is new in the management of these difficult-to-treat infections.

Keywords: Antimicrobial therapy; Cardiac implantable electronic devices; Guidelines; Infections; PK/PD.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Communicable Diseases* / therapy
  • Defibrillators, Implantable* / adverse effects
  • Defibrillators, Implantable* / microbiology
  • Device Removal / adverse effects
  • Heart Diseases* / etiology
  • Humans
  • Pacemaker, Artificial* / adverse effects
  • Prosthesis-Related Infections* / drug therapy

Substances

  • Anti-Bacterial Agents